Avinger Inc. (NASDAQ:AVGR)’s share price traded down 3.9% during trading on Thursday . The stock traded as low as $6.59 and last traded at $6.62, with a volume of 918,436 shares. The stock had previously closed at $6.89.

Several equities analysts have commented on the stock. Zacks Investment Research raised shares of Avinger from a “sell” rating to a “hold” rating in a research report on Tuesday, May 3rd. Canaccord Genuity reissued a “buy” rating and set a $20.00 target price on shares of Avinger in a research report on Wednesday, March 30th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $18.75.

The company’s market capitalization is $82.38 million. The stock has a 50 day moving average of $11.25 and a 200 day moving average of $13.05.

Avinger (NASDAQ:AVGR) last posted its earnings results on Wednesday, May 4th. The medical device company reported ($1.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.17) by $0.11. Equities research analysts expect that Avinger Inc. will post ($4.23) earnings per share for the current year.

In other Avinger news, insider Himanshu Patel sold 10,000 shares of Avinger stock in a transaction dated Friday, May 6th. The stock was sold at an average price of $13.40, for a total transaction of $134,000.00. Following the transaction, the insider now directly owns 87,220 shares in the company, valued at $1,168,748. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Donald A. Lucas sold 9,309 shares of Avinger stock in a transaction dated Friday, May 6th. The stock was sold at an average price of $12.58, for a total value of $117,107.22. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have bought and sold shares of AVGR. Thornburg Investment Management Inc. acquired a new position in Avinger during the fourth quarter valued at $1,199,000. EAM Investors LLC raised its stake in shares of Avinger by 0.4% in the fourth quarter. EAM Investors LLC now owns 116,261 shares of the medical device company’s stock worth $2,640,000 after buying an additional 457 shares during the period. Paradigm Capital Management Inc. NY raised its stake in shares of Avinger by 41.8% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 367,056 shares of the medical device company’s stock worth $8,336,000 after buying an additional 108,222 shares during the period. Finally, Morgan Stanley raised its stake in shares of Avinger by 248.5% in the fourth quarter. Morgan Stanley now owns 146,866 shares of the medical device company’s stock worth $3,335,000 after buying an additional 104,729 shares during the period.

Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses to introduce products based on its lumivascular platform, which is an intravascular image-guided system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.